SNDX Stock Forecast 2025-2026
Distance to SNDX Price Targets
SNDX Price Momentum
10 Quality Stocks Worth Considering Now
Researching Syndax (SNDX) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on SNDX and similar high-potential opportunities.
Latest SNDX Stock Price Targets & Analyst Predictions
Based on our analysis of 18 Wall Street analysts, SNDX has a bullish consensus with a median price target of $38.50 (ranging from $16.00 to $51.00). The overall analyst rating is Strong Buy (9.2/10). Currently trading at $13.46, the median forecast implies a 186.1% upside. This outlook is supported by 14 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Edward White at HC Wainwright & Co., projecting a 279.0% upside. Conversely, the most conservative target is provided by George Farmer at Scotiabank, suggesting a 18.9% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
SNDX Analyst Ratings
SNDX Price Target Range
Latest SNDX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for SNDX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 20, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $41.00 |
| Mar 4, 2025 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $51.00 |
| Mar 4, 2025 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $42.00 |
| Mar 4, 2025 | JP Morgan | Anupam Rama | Overweight | Maintains | $39.00 |
| Jan 8, 2025 | Scotiabank | George Farmer | Sector Perform | Maintains | $16.00 |
| Dec 10, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $51.00 |
| Nov 21, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $38.00 |
| Nov 19, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $45.00 |
| Nov 18, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $51.00 |
| Nov 12, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $49.00 |
| Nov 7, 2024 | Goldman Sachs | Chris Shibutani | Buy | Maintains | $33.00 |
| Nov 6, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $47.00 |
| Oct 24, 2024 | UBS | David Dai | Buy | Initiates | $37.00 |
| Oct 14, 2024 | Stifel | Bradley Canino | Buy | Maintains | $41.00 |
| Aug 16, 2024 | Citigroup | Yigal Nochomovitz | Buy | Maintains | $34.00 |
| Aug 15, 2024 | B of A Securities | Jason Zemansky | Buy | Maintains | $31.00 |
| Aug 15, 2024 | Barclays | Peter Lawson | Overweight | Maintains | $33.00 |
| Aug 15, 2024 | HC Wainwright & Co. | Edward White | Buy | Maintains | $45.00 |
| Aug 6, 2024 | JP Morgan | Anupam Rama | Overweight | Maintains | $33.00 |
| Aug 2, 2024 | HC Wainwright & Co. | Edward White | Buy | Reiterates | $41.00 |
Syndax Pharmaceuticals Inc. (SNDX) Competitors
The following stocks are similar to Syndax based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Syndax Pharmaceuticals Inc. (SNDX) Financial Data
Syndax Pharmaceuticals Inc. has a market capitalization of $1.18B with a P/E ratio of 0.0x. The company generates $23.68M in trailing twelve-month revenue with a 96.5% profit margin.
Revenue growth is -38.6% quarter-over-quarter, while maintaining an operating margin of -1,254.8% and return on equity of -75.7%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Syndax Pharmaceuticals Inc. (SNDX) Business Model
About Syndax Pharmaceuticals Inc.
Develops innovative therapies for cancer treatment.
Syndax Pharmaceuticals generates revenue through the development and commercialization of novel cancer therapies, focusing on enhancing treatment efficacy and targeting genetic causes of cancer. The company is engaged in creating a pipeline of investigational drugs, which positions it to potentially benefit from partnerships and collaborations within the pharmaceutical industry.
Syndax is dedicated to researching epigenetic therapies and immuno-oncology, which could lead to new treatment paradigms. Its mission impacts both the pharmaceutical industry and healthcare sector by offering oncologists new therapeutic options, making it a significant player in the cancer therapeutics field.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
270
CEO
Mr. Michael A. Metzger M.B.A.
Country
United States
IPO Year
2016
Website
www.syndax.comSyndax Pharmaceuticals Inc. (SNDX) Latest News & Analysis
Syndax Pharmaceuticals granted stock options for 282,000 shares to 12 new employees under its 2023 Inducement Plan. Options vest over four years, contingent on continued employment.
The grant of stock options to new employees indicates confidence in growth and retention strategies, potentially enhancing company performance and influencing stock value positively.
Syndax Pharmaceuticals will hold its Q4 2024 earnings conference call on March 3, 2025, at 8:00 AM ET, featuring company executives and analysts from major financial institutions.
The earnings call provides insights into Syndax Pharmaceuticals' financial performance and strategic direction, influencing stock valuations and investor sentiment.
Syndax Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
23 days agoRevuforj® (revumenib) generated $7.7 million in net product revenue within its first five weeks post-launch.
Strong early revenue for Revuforj® indicates promising market demand, potentially boosting investor confidence and influencing stock performance positively.
Syndax Pharmaceuticals (SNDX) reported a quarterly loss of $1.10 per share, slightly worse than the expected loss of $1.08, and a decline from a loss of $1 per share a year earlier.
Syndax's larger-than-expected quarterly loss signals ongoing financial challenges, potentially impacting investor confidence and share price stability.
Syndax Pharmaceuticals (Nasdaq: SNDX) will report its Q4 and full year 2024 financial results and provide a business update on March 3, 2025.
Syndax Pharmaceuticals' upcoming financial results and business update could impact stock performance, signaling growth potential or challenges in its cancer therapy pipeline.
Syndax Pharmaceuticals (SNDX) will participate in upcoming investor conferences, featuring CEO Michael A. Metzger and the management team.
Syndax Pharmaceuticals' CEO and management team's participation in investor conferences could enhance visibility, attract investment interest, and signal confidence in their cancer therapy pipeline.
Frequently Asked Questions About SNDX Stock
What is Syndax Pharmaceuticals Inc.'s (SNDX) stock forecast for 2025?
Based on our analysis of 18 Wall Street analysts, Syndax Pharmaceuticals Inc. (SNDX) has a median price target of $38.50. The highest price target is $51.00 and the lowest is $16.00.
Is SNDX stock a good investment in 2025?
According to current analyst ratings, SNDX has 14 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $13.46. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for SNDX stock?
Wall Street analysts predict SNDX stock could reach $38.50 in the next 12 months. This represents a 186.1% increase from the current price of $13.46. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Syndax Pharmaceuticals Inc.'s business model?
Syndax Pharmaceuticals generates revenue through the development and commercialization of novel cancer therapies, focusing on enhancing treatment efficacy and targeting genetic causes of cancer. The company is engaged in creating a pipeline of investigational drugs, which positions it to potentially benefit from partnerships and collaborations within the pharmaceutical industry.
What is the highest forecasted price for SNDX Syndax Pharmaceuticals Inc.?
The highest price target for SNDX is $51.00 from Edward White at HC Wainwright & Co., which represents a 279.0% increase from the current price of $13.46.
What is the lowest forecasted price for SNDX Syndax Pharmaceuticals Inc.?
The lowest price target for SNDX is $16.00 from George Farmer at Scotiabank, which represents a 18.9% increase from the current price of $13.46.
What is the overall SNDX consensus from analysts for Syndax Pharmaceuticals Inc.?
The overall analyst consensus for SNDX is bullish. Out of 18 Wall Street analysts, 14 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $38.50.
How accurate are SNDX stock price projections?
Stock price projections, including those for Syndax Pharmaceuticals Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
